Early results of a phase 1/2 study covering the use of revumenib (previously known as SNDX-5613) combined with decitabine/cedazuridine and venetoclax were presented at the ASH 2023 Conference held in December. This study (NCT05360160) was designed for children and adults, to treat the KMT2A and NPM1 gene mutations. Revumenib is a potent, selective inhibitor of KMT2A that has shown promising results for relapse or refractory AML.
“Acute leukemia occurs when menin interacts with KMT2A, driving cell behavior during the immature phase, causing the cells’ failure to differentiate and become active. When this happens, the immature cells also take the space of healthy cells. Revumenib targets menin to disrupt the interaction that triggers this process, allowing the immature ones to become actually mature, healthy, functioning cells.”
The dose escalation process of this study was the following:
The median age of this study was 27 years old (the range was 12-62 years old). Most patients had tried 2.5 prior treatment options. The most common side effects:
Bone marrow blasts decreased an average of 66% to 8%. And 100% of patients experienced morphologic remission (a disappearance of all cells with characteristics of cancer). Measurable residual disease was undetectable in 43% of patients. Several transitioned to a stem cell transplant and some are now in remission. This study is ongoing.
At HealthTree, we believe that patients are powerful and have an opportunity to contribute to research in an incredibly unique way. HealthTree Cure Hub empowers patients with the knowledge to actively participate in their health journeys while providing researchers with valuable insights from real-world experiences. HealthTree Cure Hub connects patients and researchers to not only accelerate the development of innovative treatments but also lays the foundation for a future where more educated patients and research leads to more effective and personalized cures. Visit HealthTree Cure Hub today to become an active participant in your care and contribute your unique experience to researchers to move closer to a cure.
For assistance setting up your HealthTree Cure Hub account, reach out to our patient navigation team by phone: 1-800-709-1113 or email: support@healthtree.org
Early results of a phase 1/2 study covering the use of revumenib (previously known as SNDX-5613) combined with decitabine/cedazuridine and venetoclax were presented at the ASH 2023 Conference held in December. This study (NCT05360160) was designed for children and adults, to treat the KMT2A and NPM1 gene mutations. Revumenib is a potent, selective inhibitor of KMT2A that has shown promising results for relapse or refractory AML.
“Acute leukemia occurs when menin interacts with KMT2A, driving cell behavior during the immature phase, causing the cells’ failure to differentiate and become active. When this happens, the immature cells also take the space of healthy cells. Revumenib targets menin to disrupt the interaction that triggers this process, allowing the immature ones to become actually mature, healthy, functioning cells.”
The dose escalation process of this study was the following:
The median age of this study was 27 years old (the range was 12-62 years old). Most patients had tried 2.5 prior treatment options. The most common side effects:
Bone marrow blasts decreased an average of 66% to 8%. And 100% of patients experienced morphologic remission (a disappearance of all cells with characteristics of cancer). Measurable residual disease was undetectable in 43% of patients. Several transitioned to a stem cell transplant and some are now in remission. This study is ongoing.
At HealthTree, we believe that patients are powerful and have an opportunity to contribute to research in an incredibly unique way. HealthTree Cure Hub empowers patients with the knowledge to actively participate in their health journeys while providing researchers with valuable insights from real-world experiences. HealthTree Cure Hub connects patients and researchers to not only accelerate the development of innovative treatments but also lays the foundation for a future where more educated patients and research leads to more effective and personalized cures. Visit HealthTree Cure Hub today to become an active participant in your care and contribute your unique experience to researchers to move closer to a cure.
For assistance setting up your HealthTree Cure Hub account, reach out to our patient navigation team by phone: 1-800-709-1113 or email: support@healthtree.org
about the author
Katie Braswell
Katie joined HealthTree as the Community Director for AML in 2021. She is a registered dietitian who previously worked at the VA hospital in Dallas, Texas where she coached veterans with blood cancer on how to use nutrition to improve their treatment outcomes and minimize cancer-related side effects. Katie is passionate about health education and patient empowerment. In her spare time, she loves to experiment with new recipes in the kitchen, spend time running outdoors and travel to new places.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.